Placebo influences on dyskinesia in Parkinson's disease

• Published in: Movement disorders Vol. 23; no. 5; pp. 700 - 707
• Main Authors: Goetz, Christopher G., Laska, Eugene, Hicking, Christine, Damier, Philippe, Müller, Thomas, Nutt, John, Warren Olanow, C., Rascol, Olivier, Russ, Hermann
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15.04.2008; Wiley
• Subjects: Antiparkinson Agents - adverse effects; Antiparkinson Agents - therapeutic use; Biological and medical sciences; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; dyskinesias; Dyskinesias - complications; Dyskinesias - diagnosis; Dyskinesias - drug therapy; Humans; Medical sciences; Multicenter Studies as Topic - statistics & numerical data; Neurology; Odds Ratio; Organic Chemicals - adverse effects; Organic Chemicals - therapeutic use; Parkinson Disease - complications; Parkinson Disease - drug therapy; Parkinson Disease - physiopathology; Parkinson's disease; placebo; Placebo Effect; Prognosis; randomized clinical trials; Randomized Controlled Trials as Topic - statistics & numerical data; sarizotan; Nervous system diseases; Parkinson's disease; Sarizotan; Parkinson disease; dyskinesias; Involuntary movement; Cerebral disorder; Central nervous system disease; Placebo; Clinical trial; randomized clinical trials; Degenerative disease; Neurological disorder; Extrapyramidal syndrome; Dyskinesia

Clinical features that are prognostic indicators of placebo response among dyskinetic Parkinson's disease patients were determined. Placebo‐associated improvements occur in Parkinsonism, but responses in dyskinesia have not been studied. Placebo data from two multicenter studies with identical...